anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one day (Cohort 1) or three days (Cohort 2) prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-981, cetuximab, avelumab, TAK-981 combined with cetuximab, or TAK-981 combined with avelumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node. Approximately six patients will be assigned to each time point cohort. Cohort assignment is not sequential and will be selected by the Investigator based on clinic logistics and patient scheduling. Should one cohort fill in advance of the other, sites will be directed by Presage to enroll patients into the second cohort only.
Laparoscopic surgery is superior to open surgery in terms of recovery time, less postoperative pain, less wound complications, shorter hospital stay, and earlier return to work. However, carbon dioxide insufflation causes several intraoperative cardiovascular, renal, and respiratory adverse effects. Regarding respiratory effects, elevated Intra-abdominal pressure and abdominal expansion shifts the diaphragm upwards. Thus, intrathoracic pressure increases, and expansion of the lungs is restricted. This is followed by a significant decrease up to 50% in pulmonary dynamic compliance and an increase in peak and plateau airway pressures. After deflation of pneumoperitoneum both the pulmonary compliance and airway pressures return to the baseline levels. High airway pressures and decreased compliance can be associated with pulmonary barotrauma, which may manifest as immediate pneumothorax. The basal lung regions are compressed during elevated IAP causing atelectasis and uneven ventilation-perfusion relationships, impairing gas exchange. Hence, the choice of ventilation mode is very important, especially in the paediatric population. Volume control ventilation (VCV) and pressure control ventilation (PCV) modes have been used but each has its own drawbacks, with the former risking increase in airway pressure when pulmonary compliance changes which can lead to barotrauma and the latter not guaranteeing the desired tidal volume which leads to hypoventilation that presents with hypercarbia. Pressure Control Ventilation - Volume Guarantee (PCV-VG) is a recent controlled ventilation mode that combines the benefits of both volume control ventilation (VCV) and pressure control ventilation (PCV) by delivering the preset tidal volume with a decelerating flow at the lowest possible peak inspiratory pressure during a preset inspiratory time and at a preset respiratory rate ensuring adequate ventilation .
Disclosed is benzamide derivative of formula (A) and pharmaceutical preparation which as an effective component contains derivative of formula (A) or benzamide derivative of formula (B) or their mixture. Pharmaceutical preparation according to the invention may be in the form for oral appliance and in this case it also contains wetting agent selected from anionic surfacely active materials and starchy derivative such as carboxymethyl starch or its salt. Pharmaceutical preparation according to the invention contains to 20 % wt. of surfacely active agent and to 20 % wt. of starchy derivative considering the weight of the effective material, and the contains of water in the pharmaceutical preparation is to 25 % wt. Disclosed is also use of the benzamide derivative of formula (A) or in its mixture with benzamide of formula (B) for preparation of antiparasital, antibacterial and anti-fugal agent as well as for food conservation, eventually in connection with starchy derivative.
<P>PROBLEM TO BE SOLVED: To provide a biologically active substance having antiinflammatory effects with low toxity.  <P>SOLUTION: The extract of characteristic ingredient of Radix Stephaniae tetrandrae (SPRST) has the antiinflammatory effects. The antiinflammatory effects of the SPRST is the result of mutual action of Tetrandrine, Fangchinokine and other effective ingredients. The SPRST is a special extract of the Chinese medicine having antiinflammatory effects with low cytotoxicity. The SPRST carries out upregulation of calcium influx and generation of active oxygen (ROS) by G protein, and has the antiinflammatory effects and protective function to ishaemic-reperfusion injury by inhibiting occurrence of Mac-1 (CD11B/CD18) by up-regulation of heterophilic leucocyte.  <P>COPYRIGHT: (C)2004,JPO
At present, the main surgical approaches for the treatment of esophagogastric junction adenocarcinoma include single left thoracic incision, 2 right epigastric incisions, 2 left epigastric incisions, 3 cervicothoracoabdominal incisions, and left thoracoabdominal combined incision and esophageal rift through the diaphragm. Siewert type I ESOPHAgogastric junction carcinoma recommends a right thoracic approach, including Ivor-LEIws and McKeown, according to the Chinese Expert consensus for surgical treatment of ESOPHAgogastric junction adenocarcinoma published in 2018. Siwert TYPE III adenoma at esophagogastric junction, esophageal hiatus through diaphragmatic approach is recommended. The surgical approach for siwert type II adenoma at the esophagogastric junction is controversial \[7,8\]. Due to the particularity of siWERT type II lymph node diffusion, it can spread to both posterior mediastinal lymph nodes and abdominal lymph nodes, and a simple esophageal hiatus through the diaphragm may not be enough to clear lymph nodes. Does a combined thoracoabdominal approach improve patient outcomes? In the 1990s and early 2000s, the Japanese Clinical Oncology Organization (JCOG) compared the efficacy of different surgical approaches for esophagogastric junction adenocarcinoma. The trial randomized patients to transesophageal hiatus or left thoracoabdominal combined approach. Results The incidence of postoperative pneumonia was significantly higher in the left thoracoabdominal approach group than in the transesophageal hiatus group (13%vs. 4%, P=0.048), there was no significant difference in the survival rate of Siewert II type ESOPHAgogastric junction tumor between the two groups (P=0.496). To provide the best, targeted treatment for patients with esophagogastric junction adenocarcinoma, radical resection of the tumor should be combined with resection of adjacent lymph nodes. Previous studies have shown that the effect of surgery on the right chest is better than that on the left. Therefore, we asked whether the endoscopic Ivor-Lewis approach was better than the laparoscopic transabdominal enlarged gastrectomy. The right thoracic approach is the recommended approach for siwert type I adenoma at the esophagogastric junction. It has obvious advantages in postoperative esophageal and cardiopulmonary function protection. Currently, there are no clinical trials of endoscopic Ivor-Lewis and laparoscopic extended abdominal gastrectomy for the treatment of siwert type II adenoma at the esophagogastric junction. Endoscopic IVOR-Lewis and laparoscopic transesophageal hiatus test provide new clinical data for the treatment of siwert TYPE II adenoma at the esophagogastric junction, and help standardize the treatment of siwert type II adenoma at the esophagogastric junction. Therefore, based on our experience and foundation of gastrointestinal surgery in the treatment of esophagogastric junction tumors, through practical observation and research on clinical experimental treatment plans, and integration of domestic superior resources, the establishment and improvement of treatment standards for esophagogastric junction adenoma will be further promoted.
Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
Thirty otherwise medically healthy males between the ages of 25 and 55 who have previously met criteria for PTSD and have undergone prolonged exposure therapy (PET) yet continue to report emotional numbing symptoms as a chief complaint will be assessed for baseline levels of plasma oxytocin (OT), markers of pro-inflammatory cytokines, total mRNA expression in peripheral blood mononuclear cells (PBMCs), self-reported emotional numbing and social connectedness, and empathy. Real-world social connectedness will be assessed using an Electronically Activated Recorder (EAR) for two days, which will randomly record 50 second snippets of audio every 9 minutes and which will allow for quantification of time spent with others. Measures of empathy will include empathic accuracy during a dynamic empathic accuracy (EA) video task, which asks participants to rate what story-tellers are feeling while they tell positively and negatively valenced autobiographical stories. Because previous studies have shown that PTSD may interfere with subtle social processing skills and because one of the primary aims of this proposal is to uncover specific biomarkers related to self-reported emotional numbing, the investigators will also assess eye gaze and arousal covariance (correlation between skin conductance of video subject and that of study participant) during the EA task. Following baseline assessments, participants will participate in 8 weeks of CBCT, which entails twice-weekly meetings consisting of didactic information sessions and approximately 20 minutes of CBCT practice. Participants will be asked to practice at home for 20 minutes per day, and will be given a audio compact discs to guide at-home meditation. Upon completion of CBCT (Time 2), and again after 8-12 weeks (Time 3), all Time 1 assessments will be repeated.
Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
The prognosis for adult acute lymphoblastic leukemia (ALL) remains poor, which contrasts with that for pediatric ALL. It is regarded that the prognostic diversity is attributable to several differences between adults and children with respect to biological characteristics of leukemic cells, tolerance to anticancer drugs, treatment itself, and so on. It has been reported that adolescent ALL patients who were treated according to the pediatric protocol had a significantly better survival than those who were treated according to the adult protocol, indicating that the difference of treatment may be of considerable importance. To test the hypothesis, the Japan Adult Leukemia Study Group (JALSG) has planned a phase 2 study to treat younger ALL patients who are negative for BCR-ABL with the pediatric regimen which was used by the Japan Association of Childhood Leukemia Study. Those who are positive for BCR-ABL can participate in a separate protocol. The regimen is especially characterized by dose-intensified L-asparaginase, high-dose methotrexate, and intensified maintenance therapy.
A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation. The concentrated esmolol formulation can include from about 25 to about 1000 mg/ml of esmolol hydrochloride, a buffering agent and a color additive. Any number of color additives may be included such as indocyanine green, phenopheylene, hemoglobin, cyanocobalamine, patent blue, and indigo carmine vitamin B2 and naturally occurring vitamins and minerals. Also, a medical product is provided that includes a colored concentrated esmolol housed in a container, and a package housing the container and instructions. Additionally a method of allowing easy identification of a concentrated esmolol formulation is provided. The method includes providing a colored concentrated esmolol formulation that has from about 25 to about 1000 mg/ml of esmolol and a color additive.
NOMAC-E2 is a novel monophasic oral contraceptive containing a fixed dose of nomegestrol acetate (2.5mg) and 17ß-estradiol (1.5mg) which is taken for 24 days followed by 4 days of placebo. The most relevant adverse clinical outcome that has been linked to the use of COCs is venous thromboembolism (VTE). Data from randomized clinical trials did not show any serious health concerns for NOMAC-E2. However, the statistical power to detect rare adverse events is limited in these studies.

PRO-E2 is a large, prospective, controlled, long-term active surveillance study to investigate the safety of NOMAC-E2 with regard to the outcomes of interest. This study follows the European Active Surveillance (EURAS) design methodology with some modifications due to country- and product-specific characteristics. The outcomes of interest will be validated via the attending physicians. A multi-faceted follow-up procedure will ensure a low loss to follow-up rate. This study will involve women from Europe and Australia who will be followed for up to 2 years. Data analysis will include multivariable techniques such as Cox regression.
The Bascom pit-pick procedure is performed under local anesthesia with the patient in a prone position, taking approximately 15-20 minutes. Pre-operative preparation includes shaving and cleaning the surgical area. Local anesthesia (lidocaine with adrenaline) is typically used, with general anesthesia as an alternative if needed. The surgical technique involves excising midline pits with a scalpel, removing infected granulation tissue and hairs through curettage or a lateral incision. Midline wounds and nearby secondary pits are sutured with polypropylene, while the lateral incision is left open and covered with a hydrofibre bandage to heal by secondary intention.
There is increasing appreciation of the complex interaction between nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D) and insulin resistance. Not only is the prevalence of NAFLD disease high among patients with T2D, the liver disease is also more progressive. Currently, the global prevalence of NAFLD in the general population (2016-2019) is 38 %. The prevalence of T2D among those with NAFLD is approximately 23 % while the prevalence of NAFLD among those with T2D can be as high as 70 %. The prevalence of nonalcoholic steatohepatitis (NASH) is approximately 7 % in the general population and 37 % among patients with T2D. Globally, the MENA and Latin America regions of the world appear to have the highest burden of both NAFLD and T2D. Compared to those with NAFLD but without T2D, those with NAFLD and T2D are at a much higher risk for disease progression to cirrhosis and for decompensated cirrhosis, hepatocellular carcinoma, and all-cause mortality. Given that highly effective new treatments are available for T2D, high risk NAFLD with T2D should be considered for these regimens. This requires implementation of risk stratification algorithms in the primary care and endocrinology practices to identify those patients at highest risk for adverse outcomes.
An application generation and implementation method and system. The application generation method includes generating and storing a transparency software application comprising multiple application software code. The application implementation method includes retrieving by the transparency software application, personal data and an address associated a point of interest associated with a user. The two dimensional mapping application is enabled and a geographical map and selections for relevant healthcare service providers specified on the geographical map are received. The transparency software application retrieves ratings and feedback data and a selection for filter criteria. The filter criteria and subsequent filter criteria are evaluated and in response a report indicating results of the evaluation is generated and stored.
TAK-935 100 mg, tablet, orally or through G-tube/PEG tube, BID from Days 1 to 10 followed by TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 11 to 20 followed by TAK-935 100 mg tablets x3, orally or through G-tube/PEG tube, BID from Days 21 to 30 in dose titration period. The dose of TAK-935 was escalated or de-escalated during Part 1 as per investigator's discretion.
An extraction device is suitable for soaking an extracted substance to obtain an extraction liquid. The extraction device includes an upper shell unit with a flow splitting hole; a lower shell unit and a filter unit. The filter unit includes an upper shell plate; a side plate set that cooperates with the upper shell unit and the upper shell plate to define an extraction chamber; a seat body set that cooperates with the upper shell unit, the upper shell plate and the side plate set to define a bypass chamber in communication with the flow splitting hole; and a filter plate that cooperates with the seat body set and the lower shell unit to define a liquid collection chamber in communication with the bypass chamber, wherein the side plate set is provided with a side filter hole and the filter plate has a plurality of lower filter holes. When the lower filter holes are blocked, the extraction liquid can still flow into the bypass chamber through the side filter holes and then flow out from the flow splitting hole so as to improve the extraction efficiency of the extraction liquid. The upper shell unit includes a surrounding wall that surrounds an axis extending up and down and has a flow splitting hole; and a top wall connected with the upper side of the surrounding wall. The lower shell unit includes a liquid collection bucket that is disposed below the upper shell unit and has a drain hole. The extraction device includes a feeding pipe that is disposed on the upper shell unit and in communication with the extraction chamber; and a liquid inlet pipe that is disposed on the upper shell unit and in communication with the extraction chamber.
Microprocessor technology is used to detect routine sounds in a substantially enclosed environment to determine normal or abnormal activity or noise within the environment (i.e., habitual behavior of an individual) A device is situated in a substantially enclosed environment with audio input device similar to a microphone and an optional visual display for interaction with the local users. The device has the ability to be controlled locally via key-pad or USB port connected to a local laptop computer, or remotely via a phone line or Ethernet connection to internet. The device further performs audio pattern recognition using waveform matching scheme to detect the occurrence of pre-programmed sounds representing routine activities. The microprocessor counts the number occurrence of each recognizable sound for a particular interval and over a length of a day or other duration and reports to a remote server. The remote server performs tracking and trending analysis to a web-based caregiver client. Significant changes are detected and reported to caregiver or family web-based client.
PCT No. PCT/JP88/00898 Sec. 371 Date May 1, 1989 Sec. 102(e) Date May 1, 1989 PCT Filed Sep. 6, 1988 PCT Pub. No. WO89/02474 PCT Pub. Date Mar. 23, 1989.This invention relates to a method of diagnosing cancerous diseases, which comprises measuring the amount of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosaminyl-transferase in body fluid and evaluating the increase in its amount for the diagnosis of hepatic diseases. AFP, CEA and  gamma -glutamyltranspeptidase have hitherto been used as tumor markers for the diagnosis of hepatic cancer. But these conventional tumor markers show a positivity rate of about 60%, making early diagnosis almost impossible. The method of this invention employs UDP-N-acetylglucosamine:glycoprotein N-acetylglucosaminyltransferase as tumor marker, whereby early diagnosis of hepatic cancer can be made almost completely.
The present invention relates to a composition for skin regeneration, anri-wrinkling, antioxidation, anti-inflammation and skin whitening. According to the present invention, deoxycholic acid promotes collagen synthesis of fibroblasts in the skin and thus has effects of regenerating skin and reducing wrinkles. Deoxycholic acid inhibits generation of free radicals and thus has an antioxidant effect. The deoxycholic acid also inhibits synthesis of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
Subjects wear Guardian™ Sensor (3) over 7 days and undergo one FST. Zeus sensor algorithm applied retrospectively to raw sensor data.
An active coil is used to deliver iTBS. The stimulation dose is 20 sessions (1800 pulses per session; 2 sessions a day, at least 1 hour apart) over the course of 2 weeks (10 days to 14 days, allow at most three breaks and only once of the longest interval of 2 days).
Humans pass through more biological milestones during gestation and the first two years of life (known as the "first 1000 days") than during any other period of development. Consequently, both intrinsic biology/physiology and extrinsic factors such as environmental exposures can have profound impacts on long-term health and disease outcomes. The purpose of this project is to develop a cohort of mother-infant dyads that can provide a collection of birth samples and be studied long-term - from pregnancy through early childhood - to help identify early life factors that influence lifelong health and disease. The study will include collection of specimens from pregnant women during each trimester of pregnancy, at delivery, and within the first few months after giving birth, as well as collection of specimens from the infants at birth and during their first two years of life. In addition to specimens, health information will be collected from the participants' electronic health records, and via questionnaires to assess health behaviors, social determinants, and environmental exposures. Participants may also consent for yearly review of state administrative data, including educational data, social services, and vital records. The specimens and data collected in this study will allow for assessment of the impact of different factors during pregnancy and early childhood on long-term health and well-being.
PURPOSE:To provide an antibody which is an immunoglobulin prepared from an egg laid by a hen immunized with a respiratory disease, having prophylactic effect against pathogen of respiratory disease and useful as an agent for spraying into nasal cavity or throat. CONSTITUTION:The objective antibody is an immunoglobulin prepared from an egg laid by a hen immunized with a pathogen of respiratory disease (e.g. influenza virus) and having prophylactic effect against the pathogen of said respiratory disease. The antibody is especially suitable for spraying and applicable to the respiratory tracts such as nasal cavity and throat. There is no particular restriction in the form of the spraying agent, however, an inhalation aerosol to be sprayed in the form of floating fine particles is preferable. A sufficient effect can be achieved by applying the agent at an amount to neutralize the pathogen adsorbed to the respiratory tracts. Usually, about 1-10mg of the antibody is applied before going out of door.
In patients treated with ceftriaxone the Coombs’ test may become positive. Ceftriaxone for injection, like other antibacterial drugs, may result in positive test results for galactosemia.

Nonenzymatic methods for the glucose determination in urine may give false-positive results. For this reason, urine-glucose determination during therapy with ceftriaxone should be done enzymatically.

The presence of ceftriaxone may falsely lower estimated blood glucose values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.